期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.705440
关键词
TERT promoter; telomere; urothelial carcinoma; bladder cancer; upper tract urothelial carcinoma; tumorigenesis; liquid biopsy; cell-free DNA
类别
资金
- Osaka University Grant
- JSPS KAKENHI [JP 20K18139]
Over 90% of UC patients exhibit upregulated Telomerase activity, with somatic mutations in the TERT promoter region driving tumorigenesis. TERT promoter mutation holds great potential for diagnosis and treatment of UC.
Urothelial carcinoma (UC) is a common urological malignancy with a high rate of disease recurrence. Telomerase activity, a hallmark of cancer characterized by overcoming the replicative senescence, is upregulated in over 90% of patients with UC. Somatic mutations in the promoter region of telomerase reverse transcriptase (TERT) are frequently detected in UC, and drive telomerase activity. Recent studies have demonstrated a strong association between TERT promoter mutation and tumorigenesis of UC. Also, TERT promoter mutation has great potential for diagnosis, as well as prognosis in UC treatment, and this is also applicable for the liquid biopsy techniques. In this review, we discuss the progress in these areas and highlight the challenges, clinical potential, and future direction for developing UC treatment methods.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据